efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi]
efavirenz
RxCUI: 2043464
What the CMS Formulary Data Shows for efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi]
Per the CMS 2026 Part D formulary file, efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] (RxNorm concept RXCUI 2043464, generic name efavirenz) appears on 3 distinct formulary files spanning 117 Medicare Part D plan offerings - 2.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.7.
Real-world access to efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 33.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,779 Part D beneficiaries filled efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] in 2023, with total plan-and-beneficiary spending of $6,923,722 and an average per-beneficiary annual cost of $3,891.92. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] today.
Coverage Details
- Formularies covering
- 3
- Plans covering
- 117
- Coverage rate
- 2.3%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 33.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,779
- Total spending
- $6,923,722
- Avg per beneficiary
- $3,891.92
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] covered by Medicare Part D?
Yes, efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] is covered by 117 Medicare Part D plans (2.3% of all Part D formularies).
What tier is efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] on Medicare Part D plans?
efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] averages Tier 3.7 across Part D plans, ranging from Tier 1 to Tier 5.
Does efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] require prior authorization?
0% of Part D formularies require prior authorization for efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi]. Step therapy: 0%. Quantity limits: 33.3%.
How much does Medicare spend on efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi]?
In 2023, total Medicare Part D spending on efavirenz 600 MG / lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Symfi] was $6,923,722, covering 1,779 beneficiaries. The average spend per beneficiary was $3,891.92.
Read our methodology - how this data is sourced, computed, and verified.